A groundbreaking annual injection designed to protect against HIV has successfully passed its first safety trial, bringing new hope for long-term prevention.
Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...
Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...
AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
A 15-year study by Kaiser Permanente Northern California reveals significant gaps in LTBI testing practices, highlighting the need for targeted strategies to prevent active TB cases.
A study presented at CROI 2025 reveals that a single-question self-efficacy measure effectively predicts ART adherence and viral load suppression among pregnant women with HIV in Malawi, offering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback